title: A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma.
abstract: BACKGROUND
  We conducted a phase II trial to evaluate the efficacy and safety of liposomal formulation of doxorubicin in recurrent ovarian carcinoma patients.
  
  
  METHODS
  Thirty patients were included in the study after having obtained an informed consent. Their main characteristics were: median age, 64 years (range, 45-80), ECOG performance status 0 in 17 patients (56%), 1 in 11 patients (36%) and 2 in 2 patients (6.6%). Eighteen patients had metastatic disease and 12 locally advanced disease. All patients were pretreated with a platinum-based chemotherapy: 3 were considered refractory to platinum (progression or stable disease), 2 were platinum resistant (relapse < 12 months), and 7 were platinum sensitive (relapse > or = 12 months). Treatment consisted of liposomal doxorubicin, 50 mg/m2 every 4 weeks.
  
  
  RESULTS
  The overall response rate was 26.6%, with 2 complete responses and 6 partial responses lasting 3.5 months. The incidence of grade 3-4 toxicity was 23.3% for neutropenia, 10% for mucositis and 10% for plantar-palmar erythrodysesthesia. Median survival was 12+ months (range, 2-26+).
  
  
  CONCLUSIONS
  Liposomal doxorubicin appears to be a moderately active drug in pretreated patients, and its activity seems to be similar to that reported for other active regimens in terms of response rate. The toxicological profile of liposomal doxorubicin suggests that it may be combined with other drugs in the treatment of patients with ovarian cancer.
authors.affiliation: Division of Medical Oncology, St. Chiara Hospital, Trento, Italy. arcuric@yahoo.it
authors.forename: Carmela
authors.initials: C
authors.lastname: Arcuri
authors.forename: Roberto
authors.initials: R
authors.lastname: Sorio
authors.forename: Germana
authors.initials: G
authors.lastname: Tognon
authors.forename: Angela
authors.initials: A
authors.lastname: Gambino
authors.forename: Simona
authors.initials: S
authors.lastname: Scalone
authors.forename: Antonio
authors.initials: A
authors.lastname: Lucenti
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
authors.forename: Francesco
authors.initials: F
authors.lastname: Valduga
authors.forename: Emilio
authors.initials: E
authors.lastname: Arisi
authors.forename: Enzo
authors.initials: E
authors.lastname: Galligioni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D017671:Platinum Compounds; D004317:Doxorubicin